Document is current

Article History

Received: 24 July 2023

Accepted: 18 October 2023

First Online: 30 October 2023

Declarations

:

: The study protocol, amendments, and patient-related documents, were approved by the Independent Ethics Committee (IEC/IRB) of Ile de France VI – Groupe Hospitalier Pitié-Salpêtrière 47, boulevard de l’hôpital 75013 Paris, France (n° 128–15, Eudra-CT: 2015–001150-15).Written informed consent was obtained from all the participants.All experiments were performed in accordance with relevant guidelines and regulations.

: Not applicable.

: AC reports grants and nonfinancial support from Medday, during the conduct of the study; personal fees from Medday, personal fees from Merck, grants from Octapharma, grants and personal fees from Novartis, grants and personal fees from Roche, and grants and personal fees from Biogen, outside the submitted work.EH has nothing to disclose.FS was employee and shareholder of Medday; personal fees from medday pharmaceuticals, outside the submitted work; In addition, FS has a patent Pharmaceutical Compositions highly dosed with Biotin EP2555771/ US 20130084334 with royalties paid to Medday, a patent Method of treating Amyotrophic Lateral Sclerosis and neuropathies with Biotin EP 3273957/ US 20190314342 issued, and a patent Methods of Treating Multiple Sclerosis with Biotin EP2729143/US 20140030331 with royalties paid to Medday.LLV is an employee of ATLANSTAT.JPL has nothing to disclose.